These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33105031)

  • 1. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
    Menter T; Tzankov A; Dirnhofer S
    Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
    Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment signaling and therapeutics in cancer progression.
    Goenka A; Khan F; Verma B; Sinha P; Dmello CC; Jogalekar MP; Gangadaran P; Ahn BC
    Cancer Commun (Lond); 2023 May; 43(5):525-561. PubMed ID: 37005490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
    Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
    Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.
    Mulder TA; Wahlin BE; Österborg A; Palma M
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
    Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
    J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
    Liu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Aug; 14(1):125. PubMed ID: 34404434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
    Chen JA; Ma W; Yuan J; Li T
    Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory Drugs for the Treatment of B Cell Malignancies.
    Ioannou N; Jain K; Ramsay AG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.
    Ansell SM
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):618-621. PubMed ID: 29222312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Hav M; Colombo A; Chavez EA; Nissen M; Wang X; Miyata-Takata T; Lam V; Viganò E; Woolcock BW; Telenius A; Li MY; Healy S; Ghesquiere C; Kos D; Goodyear T; Veldman J; Zhang AW; Kim J; Saberi S; Ding J; Farinha P; Weng AP; Savage KJ; Scott DW; Krystal G; Nelson BH; Mottok A; Merchant A; Shah SP; Steidl C
    Cancer Discov; 2020 Mar; 10(3):406-421. PubMed ID: 31857391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
    Hatic H; Sampat D; Goyal G
    Ann Transl Med; 2021 Jun; 9(12):1037. PubMed ID: 34277837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
    Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
    BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.